Table 1.
Clinical characteristics of sampled diabetic and nondiabetic patients with FSGS and membranous nephropathy at the Center for Glomerular Diseases of Columbia University
| Characteristics | Diabetic Cohort | Age-Matched CureGN Controls | P Value |
| FSGS, n | 22 | 44 | |
| Age at first biopsy, yr | 60.0±11.7 | 59.5±11.8 | 0.90 |
| Serum creatinine, mmol/L | 2.54±2.85 | 1.94±0.97 | 0.20 |
| eGFR, ml/min per 1.73 m2 | 47.0±36.2a | 41.5±19.9a | 0.40 |
| Proteinuria, g/g or g/d | 7.1±4.6 | 5.0±4.4 | 0.09 |
| MN, n | 26 | 52 | |
| Age at first biopsy, yr | 61.3±11.1 | 61.3±11.1 | >0.99 |
| Serum creatinine, mmol/L | 1.35±0.68 | 1.39±0.78 | 0.80 |
| eGFR, ml/min per 1.73 m2 | 62.0±29.4 | 63.2±31.5 | 0.90 |
| Proteinuria, g/g or g/d | 10.3±7.8 | 7.2±5.8 | 0.03 |
| Hematuria (dipstick), n (%) | 0.005 | ||
| None/trace | 11 (43.2) | 30 (57.7) | |
| 1+ | 3 (11.5) | 10 (19.2) | |
| 2+ | 6 (23.1) | 4 (7.7) | |
| 3+ | 6 (23.1) | 3 (5.8) | |
| Unknown | 0 | 5 (9.6) | |
| Anti-PLA2R variant, n (%) | 0.01 | ||
| Positive | 10 (38.5) | 28 (53.8) | |
| Negative | 13 (50.0) | 11 (21.2) | |
| Unknown | 3 (11.5) | 13 (25.0) |
CureGN, Cure Glomerulopathy Network; MN, membranous nephropathy; PLA2R, phospholipase A2 receptor.
a
Differences in eGFR attributed to 23% black representation in the diabetic cohort versus 14% black representation in the control group.